Evaluation the effects of Favipiravir in COVID-19 patients

Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151227025726N14

Enrollment

Registered

2020-04-10

Start date

2020-04-05

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Favipiravir (Toliddaru-Sobhan Oncology company, Iran) at dose of 1600 mg BID for one day and then 600 mg BID for totally 7 days with the standard and supportive car

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Laboratory confirmed COVID-19 with RT-PCR Age over 18 years old Oxygen saturation < 93% Fever more than 72 hours before admission Bilateral pulmonary infiltration

Exclusion criteria

Exclusion criteria: Chronic kidney Disease Acute kidney Injury Pregnancy or breastfeeding Drug allergy history Chronic liver disease Mild phase of COVID-19 Critical phase of COVID-19

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.	—

Secondary

Measure	Time frame
Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and seven and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Death. Timepoint: At end of the study. Method of measurement: Medical Record.;Needs of mechanical ventilation. Timepoint: Daily. Method of measurement: Medical Record.	—

Measure

Time frame

Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and seven and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Death. Timepoint: At end of the study. Method of measurement: Medical Record.;Needs of mechanical ventilation. Timepoint: Daily. Method of measurement: Medical Record.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Vahidi

Shahid Beheshti University of Medical Sciences

h.vahidi@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026